Clinical Trials Browser

Phase 2 × Endometrial Adenocarcinoma × Clear all

NCT00977574 2025-10-31

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Phase 2 Active not recruiting

349 enrolled 11 charts

GynecologicSarcoma

Endometrial Adenocarcinoma

NCT04106414 2025-10-14

Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment

Phase 2 Active not recruiting

GynecologicSarcoma

Endometrial Adenocarcinoma

NCT01041027 2023-10-26

Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer

Phase 2 Terminated

31 enrolled 8 charts

Endometrial Adenocarcinoma

NCT01307631 2022-02-11

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

Phase 2 Completed

37 enrolled 9 charts

Endometrial Adenocarcinoma

NCT00478426 2020-02-17

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Phase 2 Completed

34 enrolled 10 charts

GynecologicSarcoma

Endometrial Adenocarcinoma

NCT01132820 2019-08-08

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Phase 2 Completed

53 enrolled 11 charts

Endometrial Adenocarcinoma

NCT00006089 2019-07-31

Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Phase 2 Completed

Endometrial Adenocarcinoma

NCT01642082 2018-03-13

Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer

Phase 2 Completed

28 enrolled 9 charts

GenitourinaryGynecologic

Endometrial Adenocarcinoma

NCT00820898 2017-12-29

Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer

Phase 2 Completed

24 enrolled 7 charts

Endometrial Adenocarcinoma

NCT00888173 2017-12-06

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Phase 2 Completed

45 enrolled 10 charts

GenitourinaryGynecologic

Endometrial Adenocarcinoma

NCT01225887 2017-10-09

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Phase 2 Completed

37 enrolled 11 charts

GenitourinaryGynecologic

Endometrial Adenocarcinoma

NCT00064025 2016-04-11

Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

Phase 2 Completed

75 enrolled 6 charts

Endometrial Adenocarcinoma